България - български - БАБХ (Българска агенция по безопасност на храните)

industrial veterinaria, s.a. - Клозантела - инжекционен разтвор - 50 mg/ml - говеда, овце

България - български - БАБХ (Българска агенция по безопасност на храните)

industrial veterinaria, s.a. - Марбофлоксацин - инжекционен разтвор - 100 mg/ml - говеда, свине

България - български - Ecolab

ecolab deutschland gmbh -

България - български - Изпълнителна агенция по лекарствата

leo pharma a/s - Бетаметазон и антибиотици - 20 mg/g + 1 mg/g cream

България - български - Изпълнителна агенция по лекарствата

b.braun melsungen ag - Комбинация - emulsion for infusion

България - български - Изпълнителна агенция по лекарствата

b.braun melsungen ag - Комбинация - emulsion for infusion

България - български - БАБХ (Българска агенция по безопасност на храните)

industrial veterinaria, s.a. - Амоксициллина тригидрат - прах за прилагане във вода за пиене - 500 mg/g - патици, пилета, прасета, пуйки

Европейски съюз - български - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - Захарен диабет тип 2 - Лекарства, използвани при диабет - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Европейски съюз - български - EMA (European Medicines Agency)

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - Липидни модифициращи агенти - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Европейски съюз - български - EMA (European Medicines Agency)

gilead sciences ireland uc - sacituzumab govitecan - breast neoplasms; triple negative breast neoplasms - Антинеопластични средства - trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, including at least one of them for advanced disease.